Literature DB >> 14102769

MELPHALAN THERAPY IN MYELOMATOSIS.

J WALDENSTROEM.   

Abstract

Entities:  

Keywords:  CHLORAMBUCIL; ERYTHROCYTE COUNT; GERIATRICS; MACROGLOBULINEMIA; MELPHALAN; MULTIPLE MYELOMA; PROGNOSIS; PROTEIN METABOLISM; SERUM GLOBULINS; STATISTICS; URETHANE

Mesh：

Substances：

Year:  1964        PMID： 14102769      PMCID： PMC1814043          DOI： 10.1136/bmj.1.5387.859

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  7 in total

1.  Phase II trials of mitomycin C, AB-100, NSC-1026, L-sarcolysin, and meta-sarcolysin, in the treatment of multiple myeloma.

Authors:  D E BERGSAGEL
Journal:  Cancer Chemother Rep       Date:  1962-02

2.  [Clinical experiences with sarcolysin in neoplastic diseases].

Authors:  N BLOKHIN; L LARIONOV; N PEREVODCHIKOVA; L CHEBOTAREVA; N MERKULOVA
Journal:  Ann N Y Acad Sci       Date:  1958-04-24       Impact factor: 5.691

3.  Case of multiple myeloma complicated by agranulocytosis.

Authors:  J VAUGHN; S S RAPHAEL
Journal:  Br Med J       Date:  1956-01-07

4.  Treatment of multiple myeloma with urethan; experience with 66 cases over a 2 1/2 year period.

Authors:  W F LUTTGENS; E D BAYRD
Journal:  J Am Med Assoc       Date:  1951-10-27

5.  Multiple myeloma. III. Effect of urethane therapy on plasma cell growth, abnormal serum protein components and Bence Jones proteinuria.

Authors:  R W RUNDLES; M L DILLON; E S DILLON
Journal:  J Clin Invest       Date:  1950-09       Impact factor: 14.808

6.  Multiple plasmocytoma treated with urethane.

Authors:  F SALTZMAN; H BORGSTROM
Journal:  Acta Med Scand       Date:  1950

7.  Attempt at treatment of 21 patients with myeloma or macroglobulinemia with p-di-2-chlorethylamino-1-phenylalanine (melphalan)

Authors:  J BERNARD; M SELIGMANN; F DANON
Journal:  Nouv Rev Fr Hematol       Date:  1962 Jul-Aug
  7 in total
  12 in total

1.  MELPHALAN IN THE TREATMENT OF MYELOMATOSIS.

Authors:  D E SPEED; D A GALTON; A SWAN
Journal:  Br Med J       Date:  1964-06-27

2.  Skeletal surveys in multiple myeloma. Radiologic-clinical correlation.

Authors:  J I Sebes; H B Niell; G M Palmieri; T J Reidy
Journal:  Skeletal Radiol       Date:  1986       Impact factor: 2.199

Review 3.  Update on second primary malignancies in multiple myeloma: a focused review.

Authors:  O Landgren; S Mailankody
Journal:  Leukemia       Date:  2014-01-14       Impact factor: 11.528

Review 4.  Antineoplastic and immunosuppressive drugs. I. Biochemical and clinical pharmacological considerations.

Authors:  A H Chalmers; L A Burgoyne; A W Murray
Journal:  Drugs       Date:  1972       Impact factor: 9.546

Review 5.  Antineoplastic and immunosuppressive drugs. II. Therapeutic uses.

Authors:  M D Cridland
Journal:  Drugs       Date:  1972       Impact factor: 9.546

6.  The management of myelomatosis.

Authors:  A F Broad; J N Godlee; E W Emery; T A Prankerd
Journal:  Postgrad Med J       Date:  1968-10       Impact factor: 2.401

7.  [Plasmocytoma as a neurosurgical clinical picture].

Authors:  G Orf
Journal:  Acta Neurochir (Wien)       Date:  1970-04-21       Impact factor: 2.216

8.  The effect of 1-phenylalanine mustard on anti-globulin antibodies in multiple myeloma.

Authors:  M Waller; J H Moon; R Irby; E C Toone
Journal:  Clin Exp Immunol       Date:  1971-01       Impact factor: 4.330

9.  Multiple myeloma: development of plasma cell sarcoma during apparently successful chemotherapy.

Authors:  J M Holt; A H Robb-Smith
Journal:  J Clin Pathol       Date:  1973-09       Impact factor: 3.411

10.  Peptichemio induction therapy in myelomatosis.

Authors:  G Merlini; P G Gobbi; A Riccardi; G Riva; C Sardi; S Perugini
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.